This Week's Issue Sponsored by:
October 2, 2019

Inside the Market for High-Potency APIs
by Brandon Boyd, Director of Strategy & Thought Leadership, Clarivate Analytics
What's behind continuing investment in manufacturing capabilities for high-potency APIs (HPAPIs)? The potential in innovator drugs is a driving factor, but the supply opportunities for generic drugs with HPAPIs also comes into play.   Read More

Brexit & Pharma Industry: Preparing for a No Deal
by Patricia van Arnum, DCAT Editorial Director

Of the 12,300 medicines used in the UK, around 7,000 come from or via the EU, so what happens if the UK is not able to negotiate a deal as it faces an October 31 deadline to withdraw from the EU? How are the UK and the pharmaceutical industry preparing? Read More
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .